Hair loss hope: new drink targets shedding from popular Weight-Loss meds

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female gender. * Age \>35 years. * Initiation of treatment with a GLP-1/GIP agonist, or treatment duration \< 3 months, as per routine clinical practice in the endocrinology clinic. * Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study. * Additional criteria to be included by the client. Exclusion Criteria: * Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested. * Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc. * Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.). * Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded. * Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation. * Women who have used anti-hair loss products within the last 3 months. * Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.). * Women who have undergone hair transplantation within the 18 months prior to study initiation. * Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months. * Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation. * Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period. * Additional exclusion criteria to be specified by the sponsor. * Any condition that, in the investigator's opinion, makes participation in the study inappropriate.